Legislative Outlook: Riders to the User Fee Packages and Other Topics
Monday, November 2, 2026
10:45 a.m. - 12:00 p.m.
Industry panelists will present and discuss proposed changes to the statute that may accompany user fee reauthorization legislation in 2027. The panel will touch on the Fair Price Device Act and legislation related to biosimilars interchangeability (including Biosimilars pathway and the opportunity for a 505(b)(2)), least burdensome, and other topics.
Jessica Greenbaum, JD
Director, Regulatory Affairs Policy U.S., Sandoz Inc.
Brian McCormick, JD
Vice President and Chief Regulatory Counsel, Teva Pharmaceuticals
Kim Trzeciak
Vice President, Global External Affairs, USP
Andrew Zacher, JD, MS
Senior Director, Regulatory & Public Policy, Amneal Pharmaceuticals
